CHECKPOINT THERAPEUTICS, INC. Financials Checkpoint Therapeutics, Inc.
Equities
CKPT
US1628282063
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.79 USD | -2.72% |
|
-11.82% | -21.83% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 88.79 | 179.9 | 260.5 | 52.39 | 53.87 | 67.8 | - | - |
| Enterprise Value (EV) 1 | 88.79 | 179.9 | 260.5 | 52.39 | 53.87 | 67.8 | 67.8 | 67.8 |
| P/E ratio | -2.46 x | -6.46 x | -4.15 x | -0.72 x | -0.72 x | -1.2 x | 1.24 x | - |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 52 x | 168 x | 972 x | 273 x | 523 x | 76.3 x | 0.39 x | 0.71 x |
| EV / Revenue | 52 x | 168 x | 972 x | 273 x | 523 x | 76.3 x | 0.39 x | 0.71 x |
| EV / EBITDA | -3.57 x | -7.75 x | -4.59 x | -0.9 x | -1.03 x | -1.52 x | - | - |
| EV / FCF | - | - | -9.9 x | -0.91 x | -1.13 x | -1.16 x | -3.13 x | 2.27 x |
| FCF Yield | - | - | -10.1% | -110% | -88.3% | -86.4% | -31.9% | 44% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 5,162 | 6,788 | 8,377 | 10,252 | 23,526 | 36,850 | - | - |
| Reference price 2 | 17.20 | 26.50 | 31.10 | 5.110 | 2.290 | 1.790 | 1.790 | 1.790 |
| Announcement Date | 3/11/20 | 3/9/21 | 3/28/22 | 3/31/23 | 3/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1.708 | 1.069 | 0.268 | 0.192 | 0.103 | 0.8885 | 171.8 | 95.6 |
| EBITDA 1 | -24.85 | -23.2 | -56.72 | -58.33 | -52.15 | -44.6 | - | - |
| EBIT 1 | -24.85 | -23.2 | -56.72 | -58.33 | -52.15 | -47.39 | 75.05 | - |
| Operating Margin | -1,454.92% | -2,170.35% | -21,165.3% | -30,381.77% | -50,629.13% | -5,334.2% | 43.69% | - |
| Earnings before Tax (EBT) 1 | -24.71 | -23.08 | -56.67 | -62.62 | -51.85 | -51.69 | -7.4 | - |
| Net income 1 | -24.71 | -23.08 | -56.67 | -62.62 | -51.85 | -51.69 | 61.02 | - |
| Net margin | -1,446.96% | -2,159.12% | -21,145.52% | -32,616.67% | -50,336.89% | -5,817.95% | 35.52% | - |
| EPS 2 | -7.000 | -4.100 | -7.500 | -7.090 | -3.170 | -1.498 | 1.440 | - |
| Free Cash Flow 1 | - | - | -26.31 | -57.55 | -47.59 | -58.58 | -21.65 | 29.84 |
| FCF margin | - | - | -9,815.67% | -29,976.04% | -46,203.88% | -6,593.13% | -12.6% | 31.22% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/11/20 | 3/9/21 | 3/28/22 | 3/31/23 | 3/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.016 | 0.052 | 0.018 | 0.048 | 0.074 | 0.035 | 0.031 | 0.031 | 0.006 | - | 0.01 | 0.01 | 0.7147 |
| EBITDA 1 | -29.77 | - | -14.16 | - | -16.64 | -18.08 | -16.2 | - | -10.17 | -10.95 | -10.7 | -11 | -12.3 |
| EBIT 1 | -29.77 | -16.86 | -14.16 | -10.66 | -16.64 | -18.08 | -16.2 | -7.701 | -10.17 | -10.95 | -7.282 | -8.114 | -8.969 |
| Operating Margin | -186,062.5% | -32,425% | -78,688.89% | -22,216.67% | -22,491.89% | -51,665.71% | -52,241.94% | -24,841.94% | -169,483.33% | - | -72,825% | -81,145% | -1,254.98% |
| Earnings before Tax (EBT) 1 | -29.76 | -16.85 | -14.14 | -10.61 | -21.02 | -10.47 | -16.52 | -5.724 | -19.13 | -10.94 | -8.355 | -9.01 | -10.01 |
| Net income 1 | -29.76 | -16.85 | -14.14 | -10.61 | -21.02 | -10.47 | -16.52 | -5.724 | -19.13 | -10.94 | -8.355 | -9.01 | -10.01 |
| Net margin | -185,975% | -32,400% | -78,566.67% | -22,108.33% | -28,408.11% | -29,925.71% | -53,293.55% | -18,464.52% | -318,800% | - | -83,550% | -90,096.7% | -1,401.02% |
| EPS 2 | -3.900 | -2.000 | -1.600 | -1.200 | -6.610 | -0.8900 | -1.050 | -0.2900 | -1.100 | -0.3300 | -0.2733 | -0.2833 | -0.2967 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/28/22 | 5/12/22 | 8/12/22 | 11/8/22 | 3/31/23 | 5/15/23 | 8/14/23 | 11/13/23 | 3/22/24 | 5/10/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -26.3 | -57.6 | -47.6 | -58.6 | -21.7 | 29.8 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | - | - | - | - | - | 1 | 1.1 | 2.23 |
| Capex / Sales | - | - | - | - | - | 112.55% | 0.64% | 2.34% |
| Announcement Date | 3/11/20 | 3/9/21 | 3/28/22 | 3/31/23 | 3/22/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.84
USD
Average target price
17.25
USD
Spread / Average Target
+837.50%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -21.83% | 67.8M | |
| +54.05% | 63.85B | |
| -2.02% | 41.83B | |
| +40.01% | 40.47B | |
| -10.22% | 27.17B | |
| +13.42% | 26.52B | |
| -21.60% | 18.69B | |
| +2.89% | 12.73B | |
| +22.40% | 12.11B | |
| +27.49% | 12.07B |
- Stock Market
- Equities
- CKPT Stock
- Financials Checkpoint Therapeutics, Inc.
